The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Pros and cons of MRD testing in CLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares her insights on the benefits and drawbacks of testing minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL). Dr Eichhorst explains why gathering data on undetectable minimal residual disease (uMRD) is relevant in some situations, such as predicting duration of remission. Dr Eichhorst also discusses why testing MRD may not be relevant in a clinical setting, and that there is hope that MRD rates will be used more often in future clinical trials to evaluate treatment optimization. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
